Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 18 · below the Ichimoku cloud · RSI 26 (oversold) · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $3.5M | 0.00% | 352.50K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AVR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 7.18 per share. | 272.7K | $1.96M |
| Oct 4, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 7.51 - 7.78 per share. | 884.8K | $6.71M |
| Sep 30, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 7.60 - 7.72 per share. | 397.2K | $3.03M |
| Aug 27, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Sale at price 8.83 per share. | 7.8K | $68.87K |
| Aug 18, 2026 | St Denis DavidChief Operating Officer | Conversion of Exercise of derivative security at price 5.65 per share. | 60K | $339.00K |
| Aug 10, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Sale at price 9.10 - 9.30 per share. | 627.7K | $5.79M |
| Aug 5, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Sale at price 8.10 per share. | 174.7K | $1.42M |
| Aug 4, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Sale at price 8.23 - 8.30 per share. | 495.2K | $4.11M |
| Aug 2, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Sale at price 8.10 - 8.15 per share. | 524.4K | $4.25M |
| Jul 29, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Sale at price 8.04 - 8.20 per share. | 714.1K | $5.83M |
| Jul 27, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Sale at price 8.09 - 8.19 per share. | 441.5K | $3.60M |
| Jul 23, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Sale at price 8.13 per share. | 23K | $186.99K |
| Jun 4, 2026 | Roberts David BrianDirector | — | 17.6K | — |
| Jun 4, 2026 | Moss Gregory S. Esq.Director | — | 17.6K | — |
| Jun 4, 2026 | Mcdonnell MatthewChief Financial Officer | Conversion of Exercise of derivative security at price 4.84 - 6.32 per share. | 62K | $388.88K |
| Jun 1, 2026 | Knight Susan ElizabethDirector | Purchase at price 9.29 per share. | 11K | $102.23K |
| Jan 21, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.75 per share. | 5.00M | $28.75M |
| Jan 21, 2026 | L1 Capital Pty. Ltd.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.75 per share. | 5.00M | $28.75M |
| Dec 15, 2025 | Seaberg John DDirector | — | 27.8K | — |
| Dec 15, 2025 | Paterson WayneChief Executive Officer | — | 333.3K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.6 | 9.0 | -14.7 | 10.8 | 40.2 | 14.3 | -20.4 | 9.8 | -9.8 | -17.0 | +29.3% | ||
| 2025 | 11.1 | 12.9 | -48.0 | 36.0 | -14.3 | -10.6 | -15.3 | 25.2 | 11.9 | -0.2 | -8.7 | 21.7 | −10.6% |
| 2024 | — |
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Buy / hold / sell counts